May have limited writing in cover pages
Your PlexusDx provider might discuss higher doses in exceptional circumstances with clear medical justification and enhanced monitoring, but this represents off-label prescribing requiring thorough discussion of risks and benefits
BMI requirements and off-label use Traditional semaglutide prescribing guidelines follow FDA approval criteria, which typically need: A BMI of 30 or higher (classified as obese), or A BMI of 27 or higher (classified as overweight) with at least one weight-related condition such as high blood pressure, elevated cholesterol, or type 2 diabetes Edens licensed providers follow standard guidelines but may consider individual factors beyond basic BMI cutoffs when its clinically appropriate
Gauge and length guide by body type Your body composition determines the optimal needle length
For selected symptomatic patients please review Figure 1: B 12 Test Result Review and Process Algorithm for Patients with Risk Factor for B 12 Deficiency* and/or Non-specific** or Specific Symptom of B 12 Deficiency
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial
